Despite the advances in diabetes management, people with diabetes are not reaching their target glycemic goals. Healthcare professionals often fail to initiate, escalate, or de-intensify therapy when indicated. There are several organizations that provide guidance on the management of diabetes to assist the practitioner in achieving improved glycemic control, and this can cause confusion to the practitioner on which organizations' guidance to follow. Diabetes mellitus is associated with an elevated risk of cardiovascular disease, and there have been studies that suggest some antidiabetic medications increase cardiovascular risk and some reduce cardiovascular risk. Diabetes organizations recommend the individualization of treatment goals and choices of drug therapy that will be safe and effective. Healthcare professionals should be knowledgeable and equipped to decide on the best treatment regimen for each of their patients with type 2 diabetes (T2D) and be familiar with how to utilize the different organizations' philosophies in treating their patients.
Introduction
Battling diabetes is a global challenge. Diabetes is not a disease of rich or poor nations but all nations. It is projected that the number of diabetics globally will increase from 387 million in 2014 to 592 million by 2035. 1 The World Health Organization 2016 Global Report on diabetes has reported that the prevalence of diabetes has nearly doubled since 1980, rising from 4.7 to 8.5% in the adult population. 2 In 2015, it was reported that the cost of diabetes worldwide was 1.31 trillion US dollars of which two-thirds were direct medical costs and onethird were indirect costs, such as loss of productivity. 3 Despite the increasing numbers of new diabetic medications and technology, people with diabetes are not achieving their target glycemic goals, which results in poor health outcomes. 4, 5 Both the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) suggested that tight glycemic control, HbA1c <7% (53 mmol/mol), demonstrated a reduction in microvascular complications and possibly macrovascular complications. 5 Professional consensus reports identify how and when treatments should be used, but healthcare providers often fail to initiate or escalate therapy when indicated. The term 'clinical inertia' defines the failure of healthcare providers to advance therapy or de-intensify treatment when it is appropriate. 4, 5 The causes of clinical inertia are multifactorial. The contributing factors are physician, patient, and health system related. Some key factors are poor communication between health providers and the patient, no team approach to care, fear of hypoglycemia, adverse events, and affordability of medications. The professional organizations that guide the management of diabetes are the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American Association of Clinical Endocrinology/American College of Endocrinology (AACE/ ACE), Endocrine Society, and American College of Physicians (ACP). These organizations agree on the individualization of treatment based on patient-specific factors to reduce morbidity and mortality. The approach to therapeutic recommendations for the treatment of hyperglycemia in people with T2D varies for each organization. This often leads to confusion among healthcare professionals on how to select the appropriate medications and when to intensify therapy. To overcome clinical inertia, healthcare professionals need to be educated on how to use the diabetes organizations' recommendations for the treatment of hyperglycemia in people with T2D. The goal of this review is to assist healthcare professionals on how to use each organization's document and to differentiate among their target goals and recommendations for the treatment of people with T2D.
Diagnosis of type 2 diabetes and target goals
The current recommendations by the professional organizations to diagnose prediabetes and diabetes are based on one or four glucose abnormalities: fasting plasma glucose (FPG), random elevated glucose with symptoms, glycated hemoglobin (HbA1c), and abnormal oral glucose tolerance test. The current recommendations are summarized in Table 1 . [6] [7] [8] [9] [10] Unless there is a clear diagnosis of diabetes where a patient demonstrates symptomatic hyperglycemia and a random blood glucose >200 mg/dL (11.1 mmol/L), the diagnosis of diabetes will require repeating the measurement. [6] [7] [8] [9] [10] The repeat test can be from the same sample or on a subsequent day. [6] [7] [8] [9] [10] If two different tests demonstrate the diagnosis of diabetes, additional testing is not needed. [6] [7] [8] [9] [10] Healthcare providers need to be aware of conditions that may affect the HbA1c levels such as not using a standardized laboratory, sickle cell disease, blood loss or recent transfusion, iron deficiency anemia, erythropoietin therapy, hemodialysis, second and third trimester of pregnancy, and postpartum. 6, 11 Plasma blood glucose should be used in those circumstances to diagnose diabetes. 6, 11 Screening for asymptomatic T2D can lead to its earlier diagnosis and treatment. Each organization has criteria for screening and how often patients should be tested. Some of the risk factors for developing T2D includes age above 45, ethnic/racial background (African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific Islanders), family history, history of gestational diabetes, polycystic ovary syndrome, sedentary lifestyle, and metabolic syndrome (obesity, increased waist circumference, hypertension [HTN] , and hyperlipidemia). The Diabetes Prevention Program Research Group studied adults in the United States that were at high risk for T2D. The study was designed to see if lifestyle changes (intensive training in diet and exercise) or treatment with metformin would reduce the incidence of diabetes in persons at high risk. 12 The incidence of diabetes was reduced by 58% with lifestyle changes and by 31% with metformin as compared to placebo. 12 Similar results were seen in other studies such as the Finnish Diabetes Prevention Study that looked at just lifestyle changes (intensive training in diet and exercise). 13 Lifestyle changes should include an individualized plan that addresses dietary changes, physical activity, weight loss, smoking cessation, and psychological support. 14, 15 The consensus statement from the ADA/EASD for 2019 and the recently published ADA Standards of Care 2020 focus on a patient-centered approach to care. 14 The consensus of all the major diabetes organizations is that glycemic treatment targets should be individualized and take into consideration the patient's age, comorbidities, life expectancy, risk of hypoglycemia, and patient preferences. 7, [14] [15] [16] Target glycemic goals differ among the different organizations and are summarized in Table 2 . The ACP guidelines changed in 2018 where they raised the goal of the HbA1c levels to be 7-8% for most patients with type 2 diabetes. 16 The Endocrine Society, the ADA, the American Association of Clinical Endocrinologists, and the American Association of Diabetes Educators issued a joint statement strongly disagreeing with the ACP and proposing new guidelines. 17, 18 These organizations believe that the ACP did not take into consideration the differences of the patient populations in the trials Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease -PreterAx and DiamicroN Modified Release Controlled Evaluation (ADVANCE), UKPDS, and Veterans Affairs Diabetes Trial (VADT), which analyzed the long-term benefits of lower HbA1c levels and the positive impact of newer medications. [16] [17] [18] Common HbA1c target goals advocated by the other diabetes organizations are levels of 6.5-7% for most patients with T2D. Higher HbA1c goals are individualized based  on risk for adverse effects such as hypoglycemia, comorbidities,  age, life expectancy, and patient preferences. The Endocrine  Society and the American Diabetes Association/EASD have  addressed specific HbA1c target goals for the elderly, which  are included in Table 2 . 19, 20 Abnormal glucose metabolism and cardiovascular disease (CVD) are risk factors for each other. 8, 21, 22 Cardiovascular risk is significantly higher in patients with T2D.
Cardiovascular disease and diabetes
T2D is associated with an elevated risk of cardiovascular disease, which remains the leading cause of morbidity and mortality in this patient population. 23 Since 2001, the National Cholesterol Education Program-Adult Treatment Panel NCEP-ATP guidelines consider diabetes a risk equivalent to coronary heart disease (CHD). 24 The former recommendation stemmed from a Finnish study, 25 where T2D patients without any previous CHD events had comparable mortality risk when compared to nondiabetic patients with a previous cardiovascular event. The latest literature proposes that the CHD risk in T2D patients varies. A systematic review of 13 studies evaluating 45,108 people with or without diabetes, indicated that CHD risk was 43% lower in diabetic patients with no previous CHD compared to those without T2D with a prior myocardial infarction. 26 The 2019 American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines Table 3 . The guidelines categorize high-risk patients based on the calculation of atherosclerotic cardiovascular disease (ASCVD) outcomes. ACC developed a tool to assess the 10-year risk for the first ASCVD event as listed in Table 4 . ASCVD can be defined as acute coronary syndrome (ACS), a history of myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. 28 Hypertension and dyslipidemia, common comorbidities coexisting with T2D, are considered strong risk factors for ASCVD. Current ADA guidelines emphasize the importance of controlling individual cardiovascular risk factors in preventing or reducing ASCVD risks in patients with diabetes. An additional risk factor for morbidity and mortality from cardiovascular disease is heart failure (HF). Recent trials demonstrated a higher incidence of HF hospitalizations in those patients with T2D compared to those without diabetes. 29 The ADA recommends evaluating cardiovascular risk factors in patients with T2D annually. These risk factors include obesity (BMI >30 adult, >95 th % in children), hypertension, hyperlipidemia, smoking, chronic kidney disease, presence of albuminuria, and family history of premature coronary disease. 29 The guidelines strongly recommend treating modifiable risk factors when applicable to decrease the incidence of cardiovascular disease in diabetic individuals.
Management of hyperlipidemia
Although ASCVD risk factors are considered for selection of statin intensification therapy in the previous editions of the guidelines, the latest ACC/AHA guidelines 30 suggest treating all diabetic patients between the ages of 40 and 75 and low-density lipoprotein (LDL) levels >70 mg/dL, with a moderate-intensity statin without assessing their ASCVD 10-year risk. Diabetic individuals with additional ASCVD risk factors should be initiated on high-intensity statins with an LDL reduction goal of >50%. These additional risk enhancers include long duration (≥10 years for type 2 diabetes or ≥20 years for type 1 diabetes), albuminuria ≥30 mcg albumin/mg creatinine, estimated glomerular filtration rate (eGFR) <60 mL/ min/1.73 m 2 , ankle-brachial index <0.9, and the presence of neuropathy and retinopathy. 28 The ADA suggests a similar approach to the management of hyperlipidemia in diabetics. Recent ADA guidelines recommend initiating a moderate-ISSN: 1740-4398 REVIEW -Management of type 2 diabetes drugsincontext.com intensity statin in all diabetic individuals between the ages of 40 and 75 years. 29 The updated recommendation is to initiate a high-intensity statin for patients who have multiple risk factors for cardiovascular disease. A comprehensive list for statin therapy is outlined in Table 5 . Collectively ADA and ACC/AHA do not endorse a specific target goal for LDL levels, in contrast to recommendations provided by AACE. In 2019, AACE updated its guidelines for the management of dyslipidemia and the prevention of cardiovascular disease. 31 The guidelines advocate that the treatment goals for dyslipidemia should be individualized according to the patient's ASCVD risk. Diabetic patients without any additional risk factors are classified into the 'high risk' group with a target LDL goals of <100 mg/dL and non-HDL-C goal <130 mg/ dL. T2D with additional risk factors is considered 'very high risk' and therefore should achieve LDL levels <70 mg/dL and non-HDL-C levels <100 mg/dL.
Management of hypertension
Hypertension is defined as a sustained blood pressure (BP) >140/90 mmHg and remains common among patients with T2D. 29 As stated previously, hypertension is considered a major risk factor for macrovascular complications. Moreover, numerous studies have shown that antihypertensive therapy reduces ASCVD events, HF, and microvascular complications. 29 ADA guidelines advise a BP target of <130/80 mmHg for hypertensive individuals with T2D and high ASCVD risk of >15%. 29 For patients with a lower cardiovascular risk, the ADA recommends a BP goal of <140/80 mmHg. 29 The most recent AACE 32 guidelines recognize that elevated BP in patients with T2D has been associated with an increased risk of cardiovascular events. The AACE recommends that a BP goal should be individualized with a suggested target of <130/80 mmHg, which has been deemed appropriate for most patients. In 2017, the ACC in conjunction with the AHA and other organizations published the Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. 33 The ACC/AHA guideline suggests a BP goal of <130/80 mmHg for all patients including patients with T2D.
Diabetes and risk factors for HF
T2D is a risk factor for the development of HF. Recent evidence shows an increased risk of morbidity and mortality in patients with established HF and T2D. In the Framingham Heart Study, T2D increased the risk of HF incidence by twofold in men and four-fold in women, after adjusting for other CV risk factors. 34 Data from other literature have shown that poor glycemic control may lead to the development of HF. With each 1% increase in HbA 1 c, the risk of HF increases by 8-36%. 35, 36 In recent trials, concomitant diabetes in patients with HF has shown an increased risk of death. When considering pharmacotherapy for T2D in patients with HF, it is important to evaluate the currently available literature on the effects of antidiabetic treatment modalities on HF symptoms and exacerbations. Historically, metformin was avoided in patients with HF. Recent evidence suggests a survival benefit of using metformin in HF patients, and as of 2006, the Food and Drug Administration (FDA) has removed HF as a contraindication for metformin. 37 Thiazolidinediones are associated with increased rates of HF events and should not be used in this patient population. 38 In the SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus -Thrombolysis in Myocardial Infarction 53) trial, the risk of HF hospitalization was increased by 27%. 39 Increased HF hospitalization risk was not shown to be significantly greater for alogliptin and sitagliptin when compared to placebo in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) and the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) trials, respectively. 40, 41 Both SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) agonists may be beneficial in reducing HF hospitalizations in patients with T2D, as discussed in the next section of this paper.
T2D Treatment Modalities and Cardiovascular Disease Risk
Cardiovascular safety data A wide selection of therapies is available for the treatment of T2D. The evaluation of these therapies on cardiovascular risk permits a clinician to make a precise decision on the management of T2D. In 2008, the US FDA issued Guidance for Industry to establish the safety of a new antidiabetic therapy to treat diabetes. 42 The Guidance for sponsors states that therapy will not result in an unacceptable increase in cardiovascular risk. Moving forward, the proposal for new phase 2 and phase 3 clinical trials will have appropriate study designs for the inclusion of cardiovascular mortality, MI, and stroke. The studies may include evaluation of hospitalization for ACS, urgent revascularization procedures, and possibly other endpoints. 42 These recommendations were motivated by the high prevalence of cardiovascular disease in diabetic patients. Additionally, potential increased cardiovascular risk with the use of the peroxisome proliferator-activated receptor (PPAR) agonist rosiglitazone propelled this FDA Guidance to be issued. 43 Cardiac safety concerns were observed with increased deaths and major cardiovascular events during the development program of the PPAR agonist muraglitazar 44 increased mortality with intense glucose control in the ACCORD trial 45 and increased risk for congestive HF with pioglitazone 38 and rosiglitazone. 46 Currently, several trials are reporting significant reductions in cardiovascular events with SGLT2 inhibitors and GLP-1 agonists. Empagliflozin: Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus (EMPA-REG) 47 is a double-blind placebo-controlled trial. The study randomly assigned 7020 adult T2D patients with established CVD to receive a placebo or 10 or 25 mg of the SGLT2 inhibitor empagliflozin after a run-in period. Individuals with body mass index ≤45 kg/m 2 , hemoglobin A1c (HbA1c) of 7-10%, and an eGFR >30 mL/min/1.73 m 2 were included. At the end of the study period, the empagliflozin group met the primary endpoint of reducing major cardiac adverse events (MACE) (composite of cardiovascular death, nonfatal MI, or nonfatal stroke) by 14% with a p-value <0.001. When given in addition to standard of care, empagliflozin reduced the risk of cardiovascular death by 38%, all-cause death by 32%, and hospitalization for HF by 35% in comparison with placebo. Treatment of only 39 patients with empagliflozin on top of standard care (ACE-inhibitors, statins, and aspirin) prevents one death over a period of 3 years. Empagliflozin compares favorably to ramipril, preventing one death in 56 individuals over a treatment period of 5 years. 48 The overall incidence of nephropathy in chronic kidney disease (CKD) patients was reduced. This was observed after treatment with empagliflozin as compared with placebo (hazard ratio [HR]: 0.58; 95% CI: 0.47-0.71; p<0.001). Empagliflozin decreased the risk of acute renal failure by 1.4%. 47 Overall, EMPA-REG was an important trial examining SGLT2-I and CV efficacy and safety outcomes. The dependable design of the trial, with >99% of patients having an established CVD resulted in a strong recommendation for the use of empagliflozin in the updated ADA guidelines. 49 Similarly, canagliflozin reduced the occurrence of MACE in a group of subjects with, or at high risk for, ASCVD in the CANVAS Program Collaborative Group. The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) study 50 demonstrated that canagliflozin was superior to placebo at preventing cardiovascular events. Patients with T2D were randomized to canagliflozin 100 or 300 mg arms (n=5795) versus placebo (n=4347). Inclusion criteria encompassed patients with T2D and high cardiovascular risk ≥30 years old and a history of symptomatic atherosclerotic cardiovascular disease. In addition, individuals ≥50 years old with two of the following were enrolled: diabetes duration >10 years, systolic BP >140 mm Hg on antihypertensive therapy, current smoking, albuminuria, or high-density lipoprotein cholesterol <38.7 mg/dL. The primary outcome was the composite incidence of cardiovascular death, MI, or stroke. Canagliflozin significantly reduced MACE compared to placebo (p=0.02 for superiority, p<0.001 for noninferiority). The benefit for canagliflozin appeared to be similar for patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). An alarming secondary outcome of increased amputations was observed in the canagliflozin group 6.3 participants per 1000 patient-years versus 3.4 participants per 1000 patient-years in the placebo group (p<0.05). Progression of albuminuria was reduced in the canagliflozin group 89.4 participants per 1000 patient-years versus 128.7 participants per 1000 patient-years (p<0.05). 50 Both trials verified that SGLT2 inhibitors reduced hospitalization for HF. 47, 50 Dapagliflozin was assessed in the DECLARE-TIMI 58 51 (Dapagliflozin Effect on Cardiovascular Events -Thrombolysis in Myocardial Infarction) trial that randomized 17,150 patients with T2D with either known cardiovascular disease or at least two risk factors for cardiovascular disease. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for HF. Secondary outcomes focused on the renal effects of dapagliflozin. The results of this trial indicate that dapagliflozin is noninferior for reducing MACE in patients with T2D and high CV risk. Dapagliflozin reduced HF hospitalizations, in addition to uncovering the beneficial effect on renal outcomes that were reported. Furthermore, among patients with HFrEF, dapagliflozin reduced HF hospitalizations, CV, and all-cause mortality. However, this group comprised only about 4% of the total population. Different from canagliflozin, 51 there was no clear safety signal regarding increased amputations and or risk. These findings are consistent with other trials conducted with (SGLT-2) inhibitors.
Ertugliflozin is presently being evaluated in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS) trial. 52 The primary objective of this trial is to evaluate the noninferiority of ertugliflozin versus placebo on MACE. Secondary objectives are to demonstrate the superiority of ertugliflozin versus placebo on time to CV death or hospitalization for HF CV death and the composite for renal outcomes/renal death, dialysis/transplant, or doubling of serum creatinine from baseline. Results from this trial are pending and anticipated to be finalized by December 2019.
The injectable GLP-1 receptor agonists liraglutide and semaglutide have also shown promising cardiovascular benefits. In people with T2D with ASCVD or increased risk for ASCVD, the addition of liraglutide decreased MACE and mortality. 53 Similarly, semaglutide had favorable outcomes on cardiovascular endpoints in high-risk subjects. 54 Liraglutide was ISSN: 1740-4398 REVIEW -Management of type 2 diabetes drugsincontext.com evaluated in the liraglutide and cardiovascular outcomes in T2D (LEADER) trial. 53 66) . Saxagliptin was associated with significantly improved glycemic control and reduced the development and progression of microalbuminuria.
The results of EXAMINE trial 40 showed that the rates of major composite events were not increased with alogliptin as compared with placebo after a 40-month follow-up. A total of 5380 participants were randomized to alogliptin and the placebo groups. The primary endpoint was a composite of death from CV causes, nonfatal MI, or nonfatal stroke. The primary endpoint occurred at similar rates in the alogliptin and placebo groups (in 11.3% and 11.8% of patients, respectively, HR: 0.96; the upper boundary of the one-sided repeated CI: 1.16; p<0.001 for noninferiority; p=0.32 for superiority).
Alogliptin was neutral on CV morbidity or mortality and did not worsen preexisting HF. In addition, assessment of pro-BNP concentration from baseline to 6 months did not reveal any significant changes.
The TECOS study 41 
Renal safety data
The evidence supporting the benefit of antihyperglycemic drugs and the improvement of renal outcomes continues to accumulate as well. Empagliflozin was evaluated in the Empagliflozin and Progression of Kidney Disease in T2D (EMPA-REG) trial 66 in the placebo group. Renal-replacement therapy was initiated in 13 of 4687 patients (0.3%) in the empagliflozin group and in 14 of 2333 patients (0.6%) in the placebo group, demonstrating a relative risk reduction of 55% in the empagliflozin group.
The randomized, double-blind Canagliflozin and Renal Outcomes in T2D and Nephropathy (CREDENCE) trial was stopped early after an interim analysis indicated substantial renal and cardiovascular protective benefits. The study investigators randomized 4401 patients with T2D plus CKD who were followed for an average of 2.62 years. The primary outcome, a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 mL/min), a doubling of the serum creatinine level, or death from renal or cardiovascular causes was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (HR: 0.70; 95% CI: 0.59-0.82; p=0.00001). A 34% reduction was found in the renal composite outcome of ESRD, doubling of serum creatinine, or death from renal causes (p<0.001), and a 32% reduction was found in the relative risk of ESRD (p=0.002). 67 The CARMELINA randomized clinical trial 64 therapy. Long-term use of dulaglutide was associated with reduced composite renal outcomes in people with T2D. 68 The vast amount of recently published data from CV outcome trials places pressure on clinical guideline groups to continuously update their recommendations. Treatment algorithms take into consideration data from CV outcome trials on the CV and renal protective aspects of antidiabetics. These recommendations aim at providing a resource not only to endocrinologists but to cardiologists, nephrologists, and primary care physicians in the region. The next section of this paper will discuss the different treatment modalities for T2D and their place in therapy.
Comprehensive management of type 2 diabetes
The ADA and American Association of Clinical Endocrinologists/American College of Endocrinology publish updated recommendations on the management of patients with T2D every January to provide guidance to healthcare professionals on how to manage this challenging disease. The ADA also provides clinical updates throughout the year. Evidence-based recommendations reflect new therapies and management approaches for individualized therapy and optimal care. The ADA/EASD published the 2018 consensus report jointly on providing a patient-centered care approach to managing hyperglycemia in T2D. 14 The patientcentered care approach does not rely on a HbA1c number or an algorithm, but assesses patient-specific factors that impact choice of treatment as in Figure 1 . 14, 69 The ADA/EASD consensus has also addressed the importance of having the patient share in the decision of their management plan to have patients engage in their management. Based on recent findings from cardiovascular outcome trials, the consensus report guides healthcare professionals on how to manage hyperglycemia in patients with atherosclerotic cardiovascular disease, CKD, and HF. The consensus also considers in patients without ASCVD or CKD the need to minimize hypoglycemia and weight gain, promote weight loss, and consider the costs of therapy as shown in Figure 1 . 14, 69 The AACE/ACE glycemic control algorithm centers treatment guidance based on a patients' entry HbA1c value (<7.5%, >7.5% or >9%). 15 The order of medications and the number of medications suggested by AACE/ACE is presented in the algorithm as a hierarchy of recommended usage, and the strength of the expert consensus recommendation is represented by the length of a colored line as shown in Figure 2 . 15 Compared to the ADA/ EASD and AACE/ACE, the other diabetes organizations (ACP, International Diabetes Federation [IDF] and Endocrine Society) do not provide easy to follow guidance on how to treat patients with T2D. The ACP and IDF organizations published treatment recommendations for patients with T2D in 2017. 10, 70 All the organizations agree on individualizing therapy with a patient-centered approach to guide the choice of medication. The consensus for treating T2D is to incorporate lifestyle management such as medical nutrition therapy, exercise, weight loss, smoking cessation counseling, psychosocial care, and diabetes self-management education into a patient's treatment plan. 70, 71 The cornerstone for the treatment of T2D has been metformin unless there are contraindications. An overview of precautions and contraindications for metformin is summarized in Table 6 . Metformin is effective, safe, low in cost, does not cause weight gain or hypoglycemia, and may reduce cardiovascular events and mortality. 10, 14, 15, 19, 69, 70 The European Society of Cardiology in collaboration with the EASD released updated 2019 guidelines for diabetes, prediabetes, and heart disease recommending SGLT-2 inhibitors and GLP-1 agonists as first-line therapy for people with diabetes who have heart disease or at the risk of heart disease. 72 Recommending to start a patient on dual therapy depends on the diabetes organization. The ADA/EASD recommends considering dual therapy in a newly diagnosed patient if they have an HbA1c >1.5% (12.5 mmol/mol) above their glycemic target. 14, 69 AACE/ ACE recommends starting with dual therapy if the entry HbA1c is >7.5% or triple therapy when the entry level is >9%. 15 Therapy should be reassessed every 3-6 months and modified to avoid clinical inertia. 69 When the HbA1c is above the individualized target and medications have reached the maximum dose for the patient, then other drugs may be added to therapy. Other antihyperglycemic medications are added to therapy based on patient comorbidities, adverse effect profiles, and cost. Based on the cardiovascular outcomes and renal trials, there is now guidance on using certain GLP-1 receptor agonists and SGLT-2 inhibitors that have demonstrated CVD, renal, and HF benefit; see Table 7 for a description of trials. Studies have demonstrated that GLP-1 agonists (liraglutide, dulaglutide, and semaglutide) and SGLT-2 inhibitors (empagliflozin, and canagliflozin) with proven CVD benefit should be prescribed to patients with T2D and ASCVD. 46, [48] [49] [50] 52, 54, 55, 65 Oral semaglutide eliminates the barrier of injection and may increase the usage of GLP-1 receptor agonists. PIONEER 6 trial has demonstrated oral semaglutide is safe for patients with T2D and high CV risk. 56, 73 Among patients with T2D in whom HF exists or is of special concern, SGLT-2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) have been shown to lower the risk of HF hospitalizations. 14, 43, 69, 74, 75 There are several SGLT-2 inhibitor outcome trials: Empagliflozin 45, 55, 68, 79 The Pioneer 5 trial showed that renal safety was consistent in the GLP-1 receptor agonist class. 80 Pioglitazone and metformin may also have potential benefits in atherosclerotic cardiovascular disease, and pioglitazone may also reduce stroke risk. 14, 15 Insulin resistance has been suggested to accelerate ASCVD. Both pioglitazone and metformin are insulin sensitizers and may be beneficial in the treatment of patients with T2D and ASCVD by decreasing insulin resistance in skeletal muscle, liver, and adipocytes. The thiazolidinediones such as pioglitazone are not recommended in patients with symptomatic HF and contraindicated in New York Heart Association (NYHA) class III and IV HF. As this class of medication causes fluid retention, there is an increased risk of HF. 10, 14, 15, 19, 69 Metformin is discouraged in patients with acute HF with hypoperfusion. 81 The CAROLINA and CARMELINA cardiovascular outcome trials for linagliptin have shown cardiovascular safety. 63, 64 Saxagliptin and alogliptin DPP-4 inhibitors have been shown to have a slight increased risk of HF and should be avoided in patients with preexisting HF. 15 Both SGLT-2 inhibitors and GLP-1 receptor agonists are excellent choices for minimizing weight gain in patients with T2D, but the GLP-1 receptor agonists promote more weight loss than SGLT-2 inhibitors. The DPP-4 inhibitors and metformin are weight neutral, but the thiazolidinediones, sulfonylureas, meglitinides, and insulin cause weight gain. 10, 14, 15, 56, 69 When considering a pharmacologic agent to utilize in patients with T2D, hypoglycemia must be considered. Patients at risk for hypoglycemia should use classes of medications with a lower risk of hypoglycemia such as metformin, SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, thiazolidinediones, or the α-glucosidase inhibitors. 10, 14, 15, 56, 69 The antidiabetic classes of medications with the highest risk of hypoglycemia are the secretagogues (sulfonylureas and meglitinides) and insulins. 10, 14, 15, 69, 70 When considering antidiabetic medications there is a need to consider all the medication precautions and contraindications listed in Table 6 . Cost is another consideration when recommending specific medications for patients with diabetes. Insurance carriers all have their own formularies that list their preferred drugs. Healthcare coverage will allow only certain medications to be covered. There are many patients who have high co-pays or need to pay out of pocket for their medications, and this can be very costly. The medications that are prescribed most often and low in cost are metformin, sulfonylureas, thiazolidinediones, and human insulin. 14, 69 Medications that are prescribed most often and are high in cost are the insulin analogs, GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors. 14, 69 T2D is a progressive disease in which the pancreas cannot synthesize and secrete sufficient insulin to meet the demands of insulin-resistant patients. Both the AACE/ACE and ADA/ EASD recommend insulin therapy when patients with T2D fail to achieve their individualized target ranges. The AACE/ACE recommends insulin therapy be considered on diagnosis with or without other agents when the patient has when the patient has symptoms of hyperglycemia and weight loss or an HbA1c of 11% (>97 mmol/mol). 14, 69 The organization recommends considering combination injectable agents when the HbA1c is >10% (86 mmol/mol) and/or 2% (>23 mmol/mol) above target. 14, 69 Injectable combination agents recommended by the ADA/EASD organizations are a GLP-1 receptor agonist with basal insulin or using both prandial insulin and basal insulin together (Figure 4) . 14, 69 Therapy should be evaluated every 3-6 months and adjusted based on patient-specific targets.
symptoms of hyperglycemia and an HbA1c level above 9% (74.9 mmol/mol). 15 The type of insulin is not recommended by the organization. If on diagnosis the patient does not have symptoms and the HbA1c is >9% (74.9 mmol/mol), the organization recommends dual or triple therapy in which basal insulin therapy may be an option. 15 Basal insulin may still be recommended for patients who do not achieve their HbA1c target goal. The dose of their basal insulin is determined by the HbA1c being <8% (63.9 mmol/mol) or >8% (Figure 3 ). 15 The ADA/EASD recommends insulin therapy be considered ISSN: 1740-4398 REVIEW -Management of type 2 diabetes drugsincontext.com
The prices of the newer insulin analogs have increased in recent years, so, as a result, many patients with diabetes cannot afford to buy insulin analogs. Over the years, insulin preparations have been developed to be less immunogenic and mimic the pancreatic release of insulin. Table 8 provides a list of the most common insulin products used by healthcare professionals. Basal insulin analogs have less hypoglycemia especially nocturnal, less variability, more predictability, longer duration of action and fewer injections than human insulin. 82 NPH insulin peaks leading to a greater risk of hypoglycemia and is also given usually twice a day. 82 Patients cannot skip meals and all meals should be carbohydrate consistent at the same time each day. A systemic review and network meta-analysis published in the Annals of Internal Medicine compared basal insulin analogs used for patients with type 2 diabetes and found they did not differ substantially in their glucose-lowering effect. 83 They also stated degludec and glargine 300 may have a lower risk of nocturnal hypoglycemia than the other insulin analogs. 83 Weight gain may be less for determir and glargine 300. 82, 83 Prandial insulin analogs have been developed to mimic the pancreatic secretion of insulin when a person eats. These analogs have a faster onset and shorter duration of action than regular insulin. 82 Regular insulin needs to be taken 30 minutes before eating, and the analogs can be taken at the start of the meal or immediately after a meal. 82 Premixed insulin contains a combination of basal insulin and prandial insulin in one injection but tends to have an increased risk for hypoglycemia. Premixed insulin should be used only in patients who have consistent meals. Concentrated formulations (U-200, U-300, and U-500) of insulin are available for patients who require large doses of insulin. Insulin is now available as 'biosimilar' or 'follow-on' formulations that are less expensive and not identical to the original insulin due to a different manufacturing process. For individuals who cannot afford insulin analogs, attention has also been brought to using human insulin products. A study published in JAMA evaluated the implementation of a Health Plan Program switching patients from analog insulin to human insulin and showed there was a small increase in population-level HbA1c. 83 The World Health Organization has also published guidelines for treatment intensification in T2D and type of insulin in type 1 and type 2 diabetes in low-resource settings. 84 The recommendation from the WHO was to use short-and intermediate-acting human insulin to manage blood glucose in adults with type 1 and type 2 diabetes unless they have frequent episodes of hypoglycemia at which point long-acting insulin analogs would be used. 85 One must take into consideration that frequent episodes of hypoglycemia can cause hypoglycemia unawareness and serious adverse effects that can cause death. [86] [87] [88] The management of patients with T2D has become complex with the growing number of medications and formulations that have been approved over the past few years. All the medications approved to treat diabetes lower the glucose levels by acting on different pathways that contribute to hyperglycemia. In selecting a treatment regimen for a patient with T2D, the regimen needs to be tailored to fit that specific individual patient. Healthcare providers must take into consideration several factors when selecting a drug treatment regimen: individualized glycemic targets, age of the patient, life expectancy, comorbidities, cardiovascular risk reduction and renal protection, avoidance of hypoglycemia and other side effects of medications, weight control, cost, and patient preferences to successfully manage a patient with T2D. Healthcare providers need to deliver patient-centered care. Adherence to therapy will depend on the patient being involved with decisions on their therapy. Diabetes is a progressive disease, and it is important to initiate, escalate, or sometimes de-intensify therapy when necessary to avoid 'clinical inertia.' The response to therapy should be assessed at regular intervals for efficacy and safety, and healthcare providers should adjust regimens to maintain glycemic targets. Healthcare providers need to work together with their patients on how to achieve agreed-upon glycemic targets.
